CVS Health settles USD 315 million case and declares dividend per CVS Health stock

Published on 10/21/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS accepts safeguards in its USD 315 million DOJ settlement. CVS Health stock costs EUR 84.20 on October 21, 2026, 0.24 percent above Xetra close.

Legal costs and operating scale

CVS Health agreed to a USD 315 million settlement on October 13, 2026.
Second-quarter 2026 revenue reached USD 106.10 billion, up 7.30 percent year over year.
CVS Health stock traded at EUR 84.20 at 10:34 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.24 percent above the Xetra close of October 20, 2026.

CVS Health Corp., US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (US1266501006) agreed to pay USD 315 million to resolve allegations over unlawful opioid prescriptions on October 13, 2026. The U.S. Department of Justice said the agreement also requires stronger monitoring, a reporting hotline and reviews of suspect prescribers. CVS said it disagreed with the allegations and admitted no wrongdoing.

CVS Health stock was trading at EUR 84.20 at Lang & Schwarz on October 21, 2026 at 10:34 a.m. CEST, plus 0.24 percent versus the Xetra close of October 20, 2026 at EUR 84.00. The modest intraday premium leaves the legal settlement and the upcoming results as the clearer reference points for investors.

Three dates frame the case

On August 5, 2026, CVS reported second-quarter revenue of USD 106.10 billion, up 7.30 percent year over year, and maintained fiscal 2026 adjusted earnings-per-share guidance of USD 7.90 to USD 8.10, according to MarketBeat. On October 5, 2026, CVS scheduled its third-quarter results call for November 4, 2026, at 8:00 a.m. ET, as stated by CVS Health. The October 13 settlement was the latest of these three events and carries a USD 315 million payment.

What does the settlement change?

The financial payment is paired with operational controls rather than a simple cash charge. The Justice Department said CVS must monitor dispensing patterns, assess prescribers suspected of illegal activity and provide a hotline for employees and the public. The agency also emphasized that the resolved claims remain allegations and that there has been no determination of liability.

That distinction matters before the November 4 report. The second-quarter revenue increase of 7.30 percent and the fiscal 2026 adjusted earnings-per-share range of USD 7.90 to USD 8.10 provide the operating backdrop, while the settlement adds a concrete compliance obligation. The next report will show how management frames that obligation alongside healthcare costs and pharmacy execution.

Upcoming dividend and results dates

CVS Health's next substantiated dates are October 22, 2026, the ex-dividend date for its USD 0.665 quarterly dividend, and November 4, 2026, the third-quarter results call at 8:00 a.m. ET. MarketBeat reported the ex-dividend date and payment terms, while CVS Health confirmed the results schedule in its investor notice.

Price holds above the Xetra close

The Lang & Schwarz quote places CVS Health stock at EUR 84.20 on October 21, 2026 at 10:34 a.m. CEST, plus 0.24 percent versus the Xetra close of October 20, 2026 at EUR 84.00. The company had a market capitalization of EUR 107.4 billion as of October 20, 2026, based on the euro-listed quote.

The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.